Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5699 Target Snapshot

Serine/threonine-protein kinase SIK2 · SINGLE PROTEIN · Homo sapiens

1,133Compounds
251Assays
19Approved Drugs
616.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9H0K1. Use UniProt Q9H0K1 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9H0K1 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase SIK2 as ChEMBL target CHEMBL5699, mapped to UniProt Q9H0K1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase SIK2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5699
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H0K1
Serine/threonine-protein kinase SIK2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase SIK2 is the right protein anchor across sources, using UniProt Q9H0K1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase SIK2
UniProt AccessionQ9H0K1
Component TypeProtein
Sequence Length926 aa

Serine/threonine-protein kinase SIK2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase SIK2, mapped to UniProt Q9H0K1. Sequence length is 926 aa.

Mapped IDQ9H0K1
Review nameSerine/threonine-protein kinase SIK2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

19
Approved
7
Phase III
15
Phase II
15
Phase I
Assay Mix

Activity Type Distribution

IC50179.0
KI38.0
EC5030.0
KD369.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5090394 9.52 IC50 0.3 Preclinical
CHEMBL388978 9.51 IC50 0.306 Preclinical
CHEMBL5407103 9.4 IC50 0.4 Preclinical
CHEMBL5394880 9.22 IC50 0.6 Preclinical
CHEMBL4553284 9.22 IC50 0.6 Preclinical
CHEMBL5430450 9.21 IC50 0.61 Preclinical
CHEMBL1980995 9.2 Ki 0.631 Preclinical
CHEMBL5426204 9.19 IC50 0.64 Preclinical
CHEMBL5417444 9.15 IC50 0.7 Preclinical
CHEMBL5416410 9.1 Ki 0.7943 Approved
Distribution

pChEMBL Value Distribution

23
5.0
36
5.5
42
6.0
41
6.5
34
7.0
36
7.5
32
8.0
15
8.5
16
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
GEFITINIB
CHEMBL939
Approved 2003
Assay Landscape

Assay Landscape

251
Total Assays
235
Tested Compounds
2
Assay Types
Binding — 250 assays, 235 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 194 132 7.2
assay format 27 2 7.6
cell-based format 19 61 6.6
subcellular format 10 40 6.5
Functional — 1 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 20 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine